Clinical trials: Immunologic Deficiency Syndrome
HIV Infections
A Randomized Trial to Evaluate the Safety and Efficacy of Combination Therapy With Retrovir ( AZT ) and HIVID ( ddC ) Versus Retrovir, HIVID, and Wellferon ( Interferon Alfa-n1 ) for the Treatment of HIV Infection
Primary: To determine whether the combination of zidovudine/zalcitabine/interferon alfa-n1 (Retrovir/HIVID/Wellferon) can produce complete responses (i.e., CD4 counts return to >= 800 cells/mm3 for more than 24 weeks) in patients…
- Trial name
- NCT00002086
- Testing
- Zidovudine, Zalcitabine, Interferon alfa-n1
- Where
- 13 sites in United States
- Volunteers
- 256 people
- Sponsor
- Glaxo Wellcome
Adenosine Deaminase Deficiency
Evaluation of Adenosine Deaminase (ADA) Enzyme Deficiency in Patients With Lymphopenia and/or Elevated Immunoglobulin E
This study was designed as an observational, prospective, epidemiological screening study. Patients who have been admitted to the center and whose lymphopenia and/or Immunoglobulin E elevation has been detected in at least one…
- Trial name
- NCT05300373
- Testing
- ADENOSINE DEAMINASE TEST
- Where
- Turkey (Türkiye)
- Volunteers
- 100 people
- Sponsor
- TRPHARM
HIV Infections
Pharmacokinetic Study of Cabotegravir and Rilpivirine Long-acting Intramuscular Injections in Healthy Adult Participants
This is a phase 1, open label study in healthy participants to assess the pharmacokinetics of cabotegravir and rilpivirine in plasma following the administration of a single 600 milligram (mg) and a 900 mg intramuscular (IM)…
- Trial name
- NCT04371380
- Testing
- Cabotegravir Tablets, Rilpivirine Tablets, Cabotegravir extended release suspension for injection (long-acting)
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
HIV Infection
TMC125-C227: A Phase II Randomized, Active-Controlled, Open Label Trial to Investigate the Efficacy and Tolerability of TMC125 in HIV-1 Infected Subjects, Who Are PI-Naive and With Documented Genotypic Evidence of NNRTI Resistance From Previous NNRTI Use
The purpose of this study is to determinate the effectiveness, safety and tolerability (how well the body accepts the drug) of an investigational Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) called TMC125.
- Trial name
- NCT00225303
- Testing
- TMC125
- Volunteers
- 116 people
- Sponsor
- Tibotec Pharmaceuticals, Ireland
HIV
Ibalizumab Plus Optimized Background Regimen in Treatment-Experienced Patients With Multi-Drug Resistant HIV-1
Ibalizumab is a monoclonal antibody that works by blocking HIV entry into the immune system cells (CD4+ or T-cells) the virus typically infects.
- Trial name
- NCT02707861
- Testing
- ibalizumab, Optimized Background Regimen
- Where
- 32 sites in United States, Puerto Rico
- Volunteers
- 79 people
- Sponsor
- TaiMed Biologics Inc.
HIV Infections
Safety and Immunogenicity Study of Recombinant Modified Vaccinia Virus Ankara (MVA) Virus to Treat HIV Infection
At the end of 2004 there were more than 40 million people infected worldwide with HIV, with an estimated 16,000 new infections every day (Joint United Nations Programme on HIV/AIDS [UNAIDS], 2004).
- Trial name
- NCT00386633
- Testing
- MVA-mBN32
- Where
- Germany
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Bavarian Nordic
X-Linked Chronic Granulomatous Disease
Study of EN-374 Gene Therapy in Participants With X-Linked Chronic Granulomatous Disease
The goal of this clinical trial is to evaluate the safety and potential efficacy of the EN-374 treatment regimen and identify a dose level for further evaluation in participants with x-linked chronic granulomatous disease.
- Trial name
- NCT06876363
- Testing
- EN-374
- Where
- 9 sites in United States, United Kingdom
- Volunteers
- 15 people
- Sponsor
- Ensoma
Hepatitis C Virus (HCV)
Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With Compensated Cirrhosis and With or Without Human Immunodeficiency Virus Co-Infection
This study will evaluate the efficacy and safety of glecaprevir/pibrentasvir (ABT-493/ABT-530) in chronic hepatitis C virus (HCV) genotype (GT)1 to GT6-infected Asian participants with compensated cirrhosis with or without human…
- Trial name
- VOYAGE-2 (NCT03235349)
- Testing
- Glecaprevir/Pibrentasvir
- Where
- 34 sites in China, South Korea
- Volunteers
- 160 people
- Sponsor
- AbbVie
Hepatitis B
Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus)
This study will evaluate the efficacy and safety of bepirovirsen compared to placebo in participants with human immunodeficiency virus (HIV)/hepatitis B virus (HBV) co-infection.
- Trial name
- B-Focus (NCT06497504)
- Testing
- Bepirovirsen
- Where
- 51 sites in United States, Argentina and 8 more
- Volunteers
- 153 people
- Sponsor
- GlaxoSmithKline
HIV-1 Infection
A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-052)
The primary objectives of this study are to evaluate the antiretroviral activity of a switch to Doravirine/Islatravir (DOR/ISL) compared with continued Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) at Week 48; and…
- Trial name
- NCT05630755
- Testing
- DOR/ISL, BIC/FTC/TAF
- Where
- 49 sites in United States, Australia and 4 more
- Volunteers
- 514 people
- Sponsor
- Merck Sharp & Dohme LLC
Infection, Human Immunodeficiency Virus I, HIV Infection
KIVEXA Vs TRUVADA, Both Administered With Efavirenz, In ART-Naive Subjects
Recently, the fixed-dose combinations (FDC) KIVEXA™ (abacavir/lamivudine) and TRUVADA (tenofovir disoproxil fumarate/emtricitabine) have facilitated the usage of once-daily regimens.
- Trial name
- ASSERT (NCT00549198)
- Testing
- Abacavir/lamivudine and efavirenz, Tenofovir/Emtricitabine and efavirenz
- Where
- 68 sites in Austria, Belgium and 11 more
- Volunteers
- 392 people
- Sponsor
- GlaxoSmithKline
Herpes Simplex, HIV Infections
The Effect of Valacyclovir on the Detection of HIV From Genital Herpes Lesions in HIV-Infected Patients
The purpose of this study is to see if valacyclovir affects the detection of HIV in genital herpes lesions in HIV-infected patients. Valacyclovir is used to treat recurrent genital herpes.
- Trial name
- NCT00002404
- Testing
- Valacyclovir hydrochloride
- Volunteers
- 30 people
- Sponsor
- Glaxo Wellcome
Infection, Human Immunodeficiency Virus, HIV Infections
Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults
The Antiretroviral Therapy as Long Acting Suppression (ATLAS) study is being conducted to establish if human immunodeficiency virus type-1 (HIV-1) infected adult subjects with current viral suppression on a regimen with 2…
- Trial name
- NCT02951052
- Testing
- Cabotegravir (CAB) tablet, Rilpivirine (RPV) tablet, Cabotegravir - Injectable Suspension (CAB LA)
- Where
- 113 sites in United States, Argentina and 11 more
- Volunteers
- 618 people
- Sponsor
- ViiV Healthcare
HIV Infections
A Study on the Safety and Effectiveness of Twice-Daily Nelfinavir Plus Twice-Daily Indinavir Plus Efavirenz in HIV-Positive Patients Who Have Never Taken Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) or Protease Inhibitors
Indinavir is usually taken three times a day. The purpose of this study is to see if it is safe and effective to take indinavir only twice a day plus nelfinavir (also taken twice a day) and efavirenz (taken once a day).
- Trial name
- NCT00002235
- Testing
- Indinavir sulfate, Nelfinavir mesylate, Efavirenz
- Where
- 5 sites in United States
- Volunteers
- 6 people
- Sponsor
- Merck Sharp & Dohme LLC
Infection, Human Immunodeficiency Virus I, HIV Infection
Prospective Epidemiological Study Of The Prevalence Of HLA-B*5701 In HIV-1 Infected Patients
This study is a cross-sectional observational study to evaluate the prevalence of HLA-B*5701 in the European area and in major European ethnotypes.
- Conditions
- Infection, Human Immunodeficiency Virus I, HIV Infection, HIV-1 Infection
- Trial name
- NCT00481390
- Testing
- Cheek cells sample, Blood sample
- Where
- 20 sites in Finland, Ireland and 3 more
- Volunteers
- 1,110 people
- Sponsor
- GlaxoSmithKline
Human Immunodeficiency Virus Type 1 (HIV-1), HIV Infections
Drug Interactions Between Voriconazole and Atazanavir Coadministered as Atazanavir/Ritonavir in Healthy Participants
This study assesses the effects of voriconazole, 200 mg, administered twice daily (BID), on the steady-state pharmacokinetics of atazanavir administered as atazanavir/ritonavir, 300/100 mg once daily (QD), in healthy participants…
- Trial name
- NCT00833482
- Testing
- Voriconazole, Atazanavir, Ritonavir
- Where
- 2 sites in United States, Netherlands
- Volunteers
- 185 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
HIV Infections
Comparison of GW433908/Ritonavir to Nelfinavir When Used With Abacavir and Lamivudine in Patients That Have Not Taken Antiretroviral Drugs
The purpose of this study is to compare virus response to GW433908/ritonavir (RTV) to viral response to nelfinavir (NFV) when used with abacavir (ABC)/lamivudine (3TC) in patients that have not taken antiretroviral (ART) drugs.
- Trial name
- NCT00009061
- Testing
- Ritonavir, Abacavir sulfate, Nelfinavir mesylate
- Where
- 37 sites in United States
- Volunteers
- 624 people
- Sponsor
- Glaxo Wellcome
HIV Infections
Phase I Safety Study of a Recombinant MVA HIV Multiantigen Vaccine in HIV-infected Subjects
Monocentric study to assess the safety and immunogenicity of the recombinant MVA-HIV multiantigen vaccine MVA-mBN120B in HIV-infected subjects.
- Trial name
- NCT00623259
- Testing
- MVA-mBN120B
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Bavarian Nordic
Infection, Human Immunodeficiency Virus
A Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK2248761 Administered as an Oral Suspension to Healthy Adult Subjects
This study is a Phase I, open-label, single dose, mass balance study in a cohort of 6 healthy adult male subjects. The study will consist of: Screening evaluations, a treatment phase, and follow-up evaluations.
- Trial name
- NCT01273103
- Testing
- 200mg [14C]- GSK2248761
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- ViiV Healthcare
HIV Infections
The Safety and Effectiveness of Didanosine Plus Stavudine Plus Delavirdine Mesylate Plus MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease Inhibitors
The purpose of this study is to see if it is safe and effective to give MKC-442, didanosine (ddI), stavudine (d4T), and delavirdine (DLV) to HIV-positive patients.
- Trial name
- NCT00002420
- Testing
- Emivirine, Hydroxyurea, Delavirdine mesylate
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Bristol-Myers Squibb
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.